Mehra, Vedika;
Chhetri, Jyoti Bikram;
Ali, Samira;
Roddie, Claire;
(2023)
The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
Biology
, 12
(11)
, Article 1419. 10.3390/biology12111419.
Preview |
Text
Roddie_he Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics_VoR.pdf - Published Version Download (1MB) | Preview |
Abstract
Adoptive cell therapy (ACT) has transformed the treatment landscape for cancer and infectious disease through the investigational use of chimeric antigen receptor T-cells (CAR-Ts), tumour-infiltrating lymphocytes (TILs) and viral-specific T-cells (VSTs). Whilst these represent breakthrough treatments, there are subsets of patients who fail to respond to autologous ACT products. This is frequently due to impaired patient T-cell function or “fitness” as a consequence of prior treatments and age, and can be exacerbated by complex manufacturing protocols. Further, the manufacture of autologous, patient-specific products is time-consuming, expensive and non-standardised. Induced pluripotent stem cells (iPSCs) as an allogeneic alternative to patient-specific products can potentially overcome the issues outlined above. iPSC technology provides an unlimited source of rejuvenated iPSC-derived T-cells (T-iPSCs) or natural killer (NK) cells (NK-iPSCs), and in the context of the growing field of allogeneic ACT, iPSCs have enormous potential as a platform for generating off-the-shelf, standardised, “fit” therapeutics for patients. In this review, we evaluate current and future applications of iPSC technology in the CAR-T/NK, TIL and VST space. We discuss current and next-generation iPSC manufacturing protocols, and report on current iPSC-based adoptive therapy clinical trials to elucidate the potential of this technology as the future of ACT.
| Type: | Article |
|---|---|
| Title: | The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/biology12111419 |
| Publisher version: | https://doi.org/10.3390/biology12111419 |
| Language: | English |
| Additional information: | Copyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/4.0/). |
| Keywords: | Induced pluripotent stem cells (iPSCs); chimeric antigen receptor T-cells (CAR-Ts); tumour-infiltrating lymphocytes (TILs); natural killer (NK) cells; virus-specific T-cells (VSTs); adoptive cell therapy (ACT); manufacturing; off-the-shelf; reprogramming |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10183072 |
Archive Staff Only
 |
View Item |
